Translational data of BPX-601 Cohort 5B was presented at ASCO's Gastrointestinal Cancers Symposium, Ladenburg Thalmann analyst Wangzhi Li tells investors in a research note. BPX-601 showed robust expansion with mean peak expansion to greater than 20,000 CAR VCN/ug gDNA, hich is high for a CART in solid tumor and comparable to CD19 CART expansion in many hematologic cancer patients, adds the analyst. Li is encouraged by the data demonstrating "significant expansion, persistence and intratumoral infiltration" of BPX-601 CART cells in the "tough" pancreatic cancer patients. The analyst keeps a Buy rating on Bellicum Pharmaceuticals with a $2.60 price target.